Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;14(6):1766-1771.
doi: 10.21037/jtd-22-432.

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challenges

Eziafa I Oduah  1   2 , Chung-Shien Lee  3   4 , Nagarashee Seetharamu  4
Affiliations
Editorial

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challenges

Eziafa I Oduah et al. J Thorac Dis. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-432/coif). CSL reports consulting fees from Pharmacy Times, Annenberg, Health First and Amida Care. CSL reports honoraria for lectures from Pharmacy Times, American College of Clinical Pharmacy, HOPA Annual Conference and HOPA Mentorship Program Update. CSL serves on the advisory board of G1 Therapeutics and Takeda. CSL serves as member of HOPA Publication Committee, President of Long Island Society of Health-System Pharmacists, Chair of NYSCHP Education and Professional Development Committee, and Chair of NYSCHP Oncology Symposium. CSL has no conflicts of interests as it pertains to this manuscript. NS reports honoraria for lectures sponsored by OncLive and Total Health Conferencing. NS serves on the advisory board of AstraZeneca, Blueprint pharma, Takeda, Regeneron, Merck, Genentech, Boehringer Ingram and Mirati. NS serves as a member of Alliance Oncology Preventions Committee, member of Alliance Oncology Respiratory Committee, publications committee of IASLC and virtual mentorship committee of ASCO. NS has no conflicts of interests as it pertains to this manuscript. The other author has no conflicts of interest to declare.

Comment on

References

    1. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35. 10.1158/0008-5472.226.65.1 - DOI - PubMed
    1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67. 10.1056/NEJMoa0904554 - DOI - PubMed
    1. Lee CS, Sharma S, Miao E, et al. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. Lung Cancer (Auckl) 2020;11:73-103. 10.2147/LCTT.S258444 - DOI - PMC - PubMed
    1. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or Carboplatin– paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. 10.1016/S1470-2045(09)70364-X - DOI - PubMed